Rare Disease Gets Big Boost from California’s Stem Cell Agency

UC Irvine's Dr. Leslie Thompson and patient advocate Frances Saldana after the CIRM Board vote to approve funding for Huntington's disease If you were looking for a poster child for an unmet medical need Huntington’s disease (HD) would be high on the list. It’s a devastating disease that attacks the brain, steadily destroying the ability … Continue reading Rare Disease Gets Big Boost from California’s Stem Cell Agency

CIRM-supported Type I Diabetes treatment enters clinical trials in Europe

ViaCyte, a company that CIRM has supported for many years, has announced international expansion of a clinical trial to test their therapeutic PEC-Direct product in patients with Type I Diabetes. The first European patient in Brussels was implanted with the PEC-Direct product candidate that, in animal models, is able to form functional beta cells. Patients … Continue reading CIRM-supported Type I Diabetes treatment enters clinical trials in Europe

71 for Proposition 71

Proposition 71 is the state ballot initiative that created California's Stem Cell Agency. This month, the Agency reached another milestone when the 71st clinical trial was initiated in the CIRM Alpha Stem Cell Clinics (ASCC) Network. The ASCC Network deploys specialized teams of doctors, nurses and laboratory technicians to conduct stem cell clinical trials at … Continue reading 71 for Proposition 71

New Investment Highlights the Growing Momentum Behind Regenerative Medicine

In biotechnology, researchers often talk about the "Valley of Death." The term describes one of the toughest challenges in drug development: moving a promising scientific discovery from the laboratory into clinical testing. At this stage, many companies need substantial funding to continue development. Yet investors often wait until therapies have cleared key scientific and regulatory … Continue reading New Investment Highlights the Growing Momentum Behind Regenerative Medicine

New partnership to make CIRM supported treatment for type 1 diabetes even better

  ViaCyte, a regenerative medicine company long backed by CIRM, announced a partnership with CRISPR Therapeutics to increase the number of people with Type 1 Diabetes (T1D) who could benefit from their PEC-Direct therapeutic implant. Last year, CIRM granted ViaCyte $20 million to facilitate development of PEC-Direct, a device that both transplants pancreatic progenitor stem … Continue reading New partnership to make CIRM supported treatment for type 1 diabetes even better

Stem Cell Agency Heads to Inland Empire for Free Patient Advocate Event

I am embarrassed to admit that I have never been to the Inland Empire in California, the area that extends from San Bernardino to Riverside counties.  That’s about to change. On Monday, April 16th CIRM is taking a road trip to UC Riverside, and we’re inviting you to join us. We are holding a special, … Continue reading Stem Cell Agency Heads to Inland Empire for Free Patient Advocate Event

Friday Roundup: A better kind of blood stem cell transplant; Encouraging news from spinal cord injury trial; Finding an “elusive” cell that could help diabetics

Cool Instagram image of the week: Chemo- and radiation-free blood stem cell transplant showing promise Bubble baby disease, also known as severe combined immunodeficiency (SCID), is an inherited disorder that leaves newborns without an effective immune system. Currently, the only approved treatment for SCID is a blood stem cell transplant, in which the patient’s defective … Continue reading Friday Roundup: A better kind of blood stem cell transplant; Encouraging news from spinal cord injury trial; Finding an “elusive” cell that could help diabetics

CIRM-Funded Research Makes Multiple Headlines this Week

When it rains it pours. This week, multiple CIRM-funded studies appeared in the news, highlighting the exciting progress our Agency is making towards funding innovative stem cell research and promoting the development of promising stem cell therapies for patients. Below are highlights. Fate Therapeutics Partners with UC San Diego to Develop Cancer Immunotherapy Last week, … Continue reading CIRM-Funded Research Makes Multiple Headlines this Week

Stem Cell Stories that Caught Our Eye: New law to protect consumers; using skin to monitor blood sugar; and a win for the good guys

New law targets stem cell clinics that offer therapies not approved by the FDA For some time now CIRM and others around California have been warning consumers about the risks involved in going to clinics that offer stem cell therapies that have not been tested in a clinical trial or approved by the U.S. Food … Continue reading Stem Cell Stories that Caught Our Eye: New law to protect consumers; using skin to monitor blood sugar; and a win for the good guys

Treatments, cures and clinical trials: an in-person update on CIRM’s progress

Patients and Patient Advocates are at the heart of everything we do at CIRM. That’s why we are holding three free public events in the next few months focused on updating you on the stem cell research we are funding, and our plans for the future. Right now we have 33 projects that we have … Continue reading Treatments, cures and clinical trials: an in-person update on CIRM’s progress